# US 2025/0154247 A1 · Cancer treatment targeting dll3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154247 A1
- Document ID: US20250154247A1
- Status: Published application
- Kind: A1
- Application number: 18/836,031
- Filed: 2023-02-22
- Published: 2025-05-15
- Earliest claimed: 2022-02-23
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Nooshin Hashemi Sadraei; Mukul Minocha; Amanda Goldrick; Xi Chen; Mira Kistler
- Web page: https://patentgrep.com/patent/US20250154247A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Invention disclosed herein provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent alone, or in combination with an anti-PD-L 1 antibody and/or chemotherapeutic agents. Step dosing or extended IV infusion of the anti-DLL3 agent is also disclosed.

## Claims

### Claim 1

A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg twice every three weeks.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-DLL3 agent is administered at a dose of 10 mg, 30 mg, or 100 mg, twice every three weeks.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the anti-DLL3 agent is administered on day 1 and day 8 of a 21-day cycle.

### Claim 4

A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, wherein the anti-DLL3 agent is administered at a dose of from 20 mg to 200 mg once every three weeks.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-DLL3 agent is administered at a dose of from 20 mg to 100 mg once every three weeks.

### Claim 6 (depends on 4)

The method of claim 4, wherein the anti-DLL3 agent is administered at a dose of from 100 mg to 200 mg once every three weeks.

### Claim 7 (depends on 4, 5, 6)

The method of any one of claims 4-6, wherein the anti-DLL3 agent is administered at a dose of 20 mg, 60 mg, 100 mg, or 200 mg.

### Claim 8 (depends on 4, 5, 6, 7)

The method of any one of claims 4-7, wherein the anti-DLL3 agent is administered on day one of a 21-day cycle.

### Claim 9

A method of treating DLL3-positive cancer comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, wherein the anti-DLL3 agent is administered according to the following regimen:
a) administering the anti-DLL3 agent in a first cycle wherein (i) the anti-DLL3 agent is administered at a dose of from 1 mg to 200 mg by continuous intravenous infusion over a period of 2 days to 7 days, and (ii) after the continuous intravenous infusion, the anti-DLL3 agent is administered by a bolus intravenous infusion on day 8, day 15, or both day 8 and day 15, and
b) administering the anti-DLL3 agent according to any one of i) to iii) below:
i) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 10 mg to 100 mg starting on day 29 and once every two weeks thereafter;
ii) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 10 mg to 100 mg starting on day 22 and twice every three weeks thereafter; and
iii) administering one or more subsequent doses of the anti-DLL3 agent at a dose of from 20 mg to 200 mg starting on day 22 and thereafter once every three weeks.

### Claim 10 (depends on 9)

The method of claim 9, wherein a) the anti-DLL3 agent is administered at a dose of from 30 mg to 100 mg by continuous intravenous infusion over a period of 2 days, 3 days, 5 days or 7 days.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein a) the anti-DLL3 agent is administered at a dose of 30 mg, 50 mg, or 100 mg by continuous intravenous infusion over a period of 2 days, 3 days, 5 days or 7 days.

### Claim 12 (depends on 9, 10, 11)

The method of any one of claims 9-11, wherein a) the anti-DLL3 agent is administered at a dose of 30 mg, 50 mg or 100 mg by continuous intravenous infusion over a period of 3 days, 5 days or 7 days.

### Claim 13 (depends on 12)

The method of claim 12, wherein a) the anti-DLL3 agent is administered at a dose of 30 mg or 100 mg by continuous intravenous infusion over a period of 3 days.

### Claim 14

A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, an anti-PD-L1 antibody, and optionally one or more chemotherapeutic agents, wherein the anti-DLL3 agent is administered according to any one of a) to c) below:
a) administering the anti-DLL3 agent at a dose of from 10 mg to 100 mg once every two weeks;
b) administering the anti-DLL3 agent at a dose of from 10 mg to 100 mg twice every three weeks; and
c) administering the anti-DLL3 agent at a dose of from 20 mg to 200 mg once every three weeks.

### Claim 15 (depends on 14)

The method of claim 14, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg once every two weeks.

### Claim 16 (depends on 15)

The method of claim 15, wherein the anti-DLL3 agent is administered at a dose of 10 mg, 30 mg, 50 mg, or 100 mg once every two weeks.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the anti-DLL3 agent is administered on day 1 and day 15 of a 28-day cycle.

### Claim 18 (depends on 14)

The method of claim 14, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg twice every three weeks.

### Claim 19 (depends on 18)

The method of claim 18, wherein the anti-DLL3 agent is administered at a dose of 10 mg, 30 mg, or 100 mg, twice every three weeks.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the anti-DLL3 agent is administered on day 1 and day 8 of a 21-day cycle.

### Claim 21 (depends on 14)

The method of claim 14, wherein the anti-DLL3 agent is administered at a dose of from 20 mg to 100 mg once every three weeks.

### Claim 22 (depends on 14)

The method of claim 14, wherein the anti-DLL3 agent is administered at a dose of from 100 mg to 200 mg once every three weeks.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein the anti-DLL3 agent is administered at a dose of 20 mg, 60 mg, 100 mg, or 200 mg once every three weeks.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claims 21-23, wherein the anti-DLL3 agent is administered on day 1 of a 21-day cycle.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 14-24, wherein prior to any one of a) to c), the anti-DLL3 agent is administered in a 21-day cycle according to the following regimen: a first dose of 0 mg or 1 mg on day 1, a second dose of from 1 mg to 100 mg on day 8, and a third dose of from 10 mg to 200 mg on day 15.

### Claim 26 (depends on 25)

The method of claim 25, wherein the first dose is 1 mg on day 1, the second dose is from 10 mg to 100 mg on day 8, and the third dose is from 10 mg to 100 mg on day 15.

### Claim 27 (depends on 25)

The method of claim 25, wherein the first dose is 1 mg on day 1, the second dose is from 10 to 100 mg on day 8, and the third dose is from 20 to 200 on day 15.

### Claim 28 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 14-24, wherein prior to any one of a) to c), the anti-DLL3 agent is administered according to the following regimen in a 21-day cycle:
(i) a first dose of 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8; or
(ii) a first dose of 1 mg on day 8, a second dose of from 10 mg to 100 mg on day 15.

### Claim 29 (depends on 28)

The method of claim 28, wherein the 21-day cycle is the first cycle the anti-DLL3 is administered to the subject and wherein the second dose in (i) or (ii) is from 10 mg to 50 mg, preferably 10 mg or 20 mg.

### Claim 30 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 14-29, wherein the anti-PD-L1 antibody is a PD-L1 blocking antibody.

### Claim 31 (depends on 30)

The method of claim 30, wherein the anti-PD-L1 antibody is atezolizumab or durvalumab.

### Claim 32 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 14-31, wherein the one or more chemotherapeutic agents comprise a platinum-based chemotherapeutic agent, etoposide, or both.

### Claim 33 (depends on 32)

The method of claim 32, wherein the platinum-based chemotherapeutic agent is carboplatin or cisplatin.

### Claim 34 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 14-33, wherein the anti-DLL3 agent is administered after the administration of the anti-PD-L1 antibody and the one or more chemotherapeutic agents when given on the same day.

### Claim 35

A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent, wherein the anti-DLL3 agent is administered to the subject at a dose of from 10 mg to 200 mg once every three weeks.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anti-DLL3 agent is administered at a dose of from 10 mg to 100 mg once every three weeks.

### Claim 37 (depends on 36)

The method of claim 36, wherein the anti-DLL3 agent is administered at a dose of from 100 mg to 200 mg once every three weeks.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the anti-DLL3 agent is administered at a dose of 10 mg, 20 mg, 60 mg, 100 mg, or 200 mg.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, wherein the anti-DLL3 agent is administered on day 1 of a 21-day cycle.

### Claim 40

A method of treating DLL3-positive cancer, comprising administering to a subject in need thereof an anti-DLL3 agent comprising the amino acid sequence of SEQ ID NOs: 13 and 23, and an alkylating agent, wherein the anti-DLL3 agent is administered to the subject according to the following: a first dose of 0 mg or 1 mg on day 1, a second dose of from 10 mg to 100 mg on day 8, a third dose of from 10 mg to 200 mg on day 15, and one or more subsequent doses of from 10 mg to 200 mg starting on day 22 and once every three weeks thereafter.

### Claim 41 (depends on 40)

The method of claim 40, wherein the first dose is 1 mg, the second dose is from 10 mg to 100 mg, the third dose is from 10 mg to 200 mg, and the one or more subsequent doses are the same and are the same as the third dose.

### Claim 42 (depends on 40)

The method of claim 40, wherein the first dose is 1 mg, the second dose is 20 mg, 60 mg, or 100 mg, the third dose is 20 mg, 60 mg, or 200 mg, and the one or more subsequent doses are the same and are each 20 mg, 60 mg or 200 mg.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40-42, wherein the one or more subsequent doses are administered on day 1 of a 21-day cycle.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 35-43, wherein the alkylating agent is a platinum-based agent.

### Claim 45 (depends on 44)

The method of claim 44, wherein the platinum-based agent is lurbinectedin.

### Claim 46 (depends on 45)

The method of claim 45, wherein lurbinectedin is administered at a dose of from 2.0 mg/m2 to 3.2 mg/m2 once every three weeks.

### Claim 47 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 35-46, wherein the anti-DLL3 agent is administered after the administration of alkylating agent when given on the same day.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the anti-DLL3 agent comprises the amino acid sequence of SEQ ID NO: 14, 27 or 32.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, the method further comprises administering one or more additional therapeutic agent to the subject.

### Claim 50 (depends on 49)

The method of claim 49, wherein the one or more additional therapeutic agent is a corticosteroid, saline, or an anti-IL6 antibody.

### Claim 51 (depends on 50)

The method of claim 50, wherein the corticosteroid is dexamethasone.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49-51, wherein the one or more additional therapeutic agent is administered in cycle 1 wherein the anti-DLL3 agent is administered.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1-52, wherein the cancer is small cell lung cancer (SCLC).

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1-53, wherein the cancer is relapsed/refractory SCLC (RR SCLC) or extensive disease SCLC (ED SCLC).

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein the subject is a human.

### Claim 56 (depends on 55)

The method of claim 55, wherein the subject had at least one prior treatment of the cancer and relapsed.

### Claim 57 (depends on 56)

The method of claim 56, wherein the least one prior treatment of the cancer is platinum chemotherapy, etoposide, and optionally an anti-PD-L1 antibody.

### Claim 58 (depends on 55)

The method of claim 55, wherein the subject had no prior systemic treatment of the cancer.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, wherein the anti-DLL3 agent is tarlatamab.
